Developing an innovative pipeline of cancer therapies
Syndax is focused on developing a pipeline of targeted therapies in multiple cancer indications. The company's lead product candidate, entinostat, is an oral small molecule that is being evaluated in a Phase 3 registrational study in combination with exemestane for the treatment of advanced breast cancer. Syndax’ pipeline also includes SNDX-6352, a monoclonal antibody targeting CSF-1R, which is a critical regulator of macrophage function in the context of chronic graft versus host disease (cGvHD), a life-threatening complication of bone marrow transplant. Syndax’s third pipeline program is a small molecule targeting MLL-r fusions, which are a recently discovered class of driver mutations in pediatric and adult leukemias.